Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic... PharmacoEconomics (2017) 35:845–858 DOI 10.1007/s40273-017-0519-z ORIGINAL RESEARCH ARTICLE Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis 1 1 2,3 2 • • • • James Buchanan Sarah Wordsworth Ruth Clifford Pauline Robbe 4,5 2,3,4,6 4,5 • • Jenny C. Taylor Anna Schuh Samantha J. L. Knight Published online: 31 July 2017 The Author(s) 2017. This article is an open access publication Abstract Results Genomic testing strategies yielded the most life- Background Genomic tests may improve the stratification years/quality-adjusted life-years per patient, but were not of patients to receive new therapies in several disease cost effective compared with a threshold of £30,000 per life- areas. However, the use of expensive targeted therapies can year/quality-adjusted life-year gained. Cost-effectiveness impact on the cost effectiveness of these tests. This study acceptability curves indicated that there was some uncer- presents an economic evaluation of genomic testing in tainty surrounding this result. A genomic testing strategy chronic lymphocytic leukaemia in the context of the UK becomes the most cost-effective option if a higher end-of-life National Health Service. cost-effectiveness threshold of £50,000 is applied, if a Methods Cost-effectiveness and cost-utility analyses (us- societal costing perspective is considered in 25-year-old http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics Springer Journals

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

Loading next page...
 
/lp/springer_journal/using-genomic-information-to-guide-ibrutinib-treatment-decisions-in-3cbLUhy97e
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration; Public Health
ISSN
1170-7690
eISSN
1179-2027
D.O.I.
10.1007/s40273-017-0519-z
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial